Alfacell (ACEL) Reports Better-Than-Expected Q4 Loss
Alfacell Corporation (Nasdaq: ACEL) reports a Q4 loss of $0.06, 3 cents better than the analyst estimate of ($0.09). (only 1 analyst covers the stock)
Alfacell Corporation, a development stage company, engages in the discovery and development of therapeutic drugs for the treatment of cancer and other pathological conditions.
Alfacell Corporation, a development stage company, engages in the discovery and development of therapeutic drugs for the treatment of cancer and other pathological conditions.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Mentor Graphics Corp (MENT) Beats Q1 EPS View by 5c; Lifts FY13 Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
